Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2007

View Archived Issues

Vinorelbine-cisplatin confirmed superior in stage II-IIIA NSCLC / News in Context

Eisai: Q3 report

Recent patents report new therapeutic agents for metabolic disorders

Recent Nissan Chemical patents describe new treatment options for thrombocytopenia

Axcan updates Q1 developments

ZymoGenetics' rhThrombin BLA accepted for review

SGX reviews oncology pipeline

Ark Therapeutics discusses phase III Vitor study with regulatory agencies

Valeant acquires rights to nabilone in the U.K. and Europe

KeyNeurotek and Max-Planck sign licensing agreement

Merck begins registrations of Atripla in developing countries

Inspire to commercialize AzaSite in U.S. and Canada

Gestiva reduces cervical shortening

Canarypox HIV vaccine responses in phase II not sufficient for phase III investigation

Pipex Pharmaceuticals' Coprexa awarded NIH grant for Alzheimer's disease

Post hoc subgroup analysis for Chrysalin in fracture repair

Safety, absorption of TMC-120 assessed in women with and without HIV

Traditional Chinese preparation to enter the clinic for the treatment of allergic asthma

New agents for treating neurological disorders disclosed in recent patents

Recent patents disclose novel treatments for diabetes

Cadherin-11: a potential target against rheumatoid arthritis

Cognitive and mood improvement after guarana therapy reported

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...